Neos Therapeutics (NEOS) Stock Price, News & Analysis

Company Overview

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Key Stats

• Today's Range: $1.06 to $1.18
• 50-Day Range: $0.77 to $1.18
• 52-Week Range: $0.45 to $1.68
• Volume: 15.01 million shs
• Average Volume: 7.44 million shs
• Market Capitalization: $57.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NEOS Stock Analysis - Frequently Asked Questions

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics, Inc. (NASDAQ:NEOS) posted its earnings results on Monday, November, 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The business earned $12.54 million during the quarter.

When did Neos Therapeutics IPO?

Neos Therapeutics (NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What other stocks do shareholders of Neos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neos Therapeutics investors own include TherapeuticsMD (TXMD), Onconova Therapeutics (ONTX), Adamis Pharmaceuticals (ADMP), Acasti Pharma (ACST), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP) and AVEO Pharmaceuticals (AVEO).

Company Calendar

• Last Earnings: 11/09/2020
• Today: 7/28/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NEOS
• CIK: 1467652
• Web: www.neostx.com
• Phone: 972-408-1300
• Fax: N/A
• Employees: 213
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.90 million
• Net Margins: -38.35%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -28.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.66
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $64.65 million
• Price / Sales: 0.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.12) per share
• Price / Book: -9.58

Miscellaneous

• Outstanding Shares: 49,757,000
• Free Float: N/A
• Market Cap: $57.22 million
• Optionable: Optionable
• Beta: 1.50